Madrigal Pharmaceuticals stock declines amid market gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 23 Jan 26
Madrigal Pharmaceuticals Inc. shares fell 5.00% as the stock crossed below its 5-day SMA, indicating a bearish trend.
The decline occurred despite the broader market's positive performance, with the Nasdaq-100 up 0.41% and the S&P 500 up 0.01%. This suggests a sector rotation, where Madrigal's stock is moving against the overall market trend.
Investors may want to monitor Madrigal's performance closely, as the stock's movement could indicate underlying issues or market sentiment specific to the company.
Analyst Views on MDGL
Wall Street analysts forecast MDGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 636.22 USD with a low forecast of 527.00 USD and a high forecast of 900.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 494.690
Low
527.00
Averages
636.22
High
900.00
Current: 494.690
Low
527.00
Averages
636.22
High
900.00
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
